0.9% (w/v) sodium chloride with 5 mM phosphate buffered solution, Zilebesiran
ALN-AGT01-008
Phase 3 small_molecule active
Quick answer
0.9% (w/v) sodium chloride with 5 mM phosphate buffered solution, Zilebesiran for High cardiovascular risk, Established cardiovascular disease, Hypertension is a Phase 3 program (small_molecule) at Alnylam Netherlands B.V. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Alnylam Netherlands B.V.
- Indication
- High cardiovascular risk, Established cardiovascular disease, Hypertension
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active